The Readout Loud 384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen
30 snips
Jan 14, 2026 Mike Doustdar, the new CEO of Novo Nordisk, shares insights on his first months at the helm, focusing on the challenge of reclaiming market share in obesity treatments. He discusses a patient-first acquisition strategy and Novo’s recent $10B bid for Metsera. Venture capitalist Bob Nelsen reflects on the importance of relationships in biotech at the J.P. Morgan conference, advocating for faster FDA approvals and the integration of AI in healthcare. Both guests offer exciting glimpses into the future of biotech and the evolving landscape of patient care.
AI Snips
Chapters
Transcript
Episode notes
From Copy Boy To CEO
- Mike Doustdar described joining Novo Nordisk as a 21-year-old office clerk who wanted pocket money and stayed for purpose.
- He said seeing patients using their products gave him a lifelong sense of responsibility and impact.
Culture Explains Growth And Friction
- Doustdar said Novo grew largely through organic growth and partnerships rather than big M&A.
- He warned consensus-driven culture can slow decisions and that speed mustn't be compromised unnecessarily.
Actively Seek External Partnerships
- Doustdar urged ending "not invented here" syndrome and ramping external partnerships.
- He brought his full executive team to JPM to explore BD opportunities and reset outward engagement.